arrow
F

Fátima Galán-Sánchez

Hospital Universitario Puerta del Mar
H指数:24
被引数:2,251

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A matched case-control study on Escherichia coli factors contributing to sepsis and septic shock in bacteraemic patients

一项关于导致菌血症患者脓毒症和脓毒性休克的大肠杆菌因素的匹配病例对照研究

2026-01-120
OAAI
Impact of universal nirsevimab prophylaxis on clinical and ultrasound presentations of lower respiratory tract infections in hospitalized pediatric patients

通用尼塞韦玛预防对住院儿科患者下呼吸道感染的临床和超声表现的影响

2025-09-170
PRE
Effectiveness of oral step-down therapy and early oral switch for bloodstream infections caused by Enterobacterales: A post hoc emulation trial of the SIMPLIFY trial

肠杆菌科细菌血流感染中口服降级疗法和早期口服转换的疗效:SIMPLIFY试验的后续模拟试验

2025-07-010
OAAI
In vivo emergence of resistance to ceftazidime/avibactam through modification of chromosomal AmpC β-lactamase in Klebsiella aerogenes

产气克雷伯菌染色体AmpC β-内酰胺酶修饰对头孢他啶/阿维巴坦的体内耐药性

2024-12-050
PRE
Association of microbiological factors with mortality in Escherichia coli bacteraemia presenting with sepsis/septic shock: a prospective cohort study

微生物因素与脓毒症/脓毒性休克大肠杆菌菌血症死亡率的关系: 一项前瞻性队列研究

2024-08-010
OA
Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

抗假单胞菌 β-内酰胺类药物结构化降阶梯治疗肠杆菌血流感染的有效性和安全性 (SIMPLIFY): 一项开放标签、多中心、随机试验

2024-04-016
PRE
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections
2023-03-1512
PRE
Conventional Hospitalization versus Sequential Outpatient Parenteral Antibiotic Therapy for Staphylococcus aureus Bacteremia: Post-Hoc Analysis of a Multicenter Observational Cohort
2023-01-090
OA
Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to Enterococcus faecalis and Enterococcus faecium: a Multicenter Cohort Study from the PROBAC Project
2022-08-315
OAAI
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa

头孢哌酮,亚胺培南/瑞巴坦,头孢吡肟/他尼巴坦和头孢吡肟/齐得巴坦对头孢噻肟/他唑巴坦和头孢他啶/阿维巴坦耐药铜绿假单胞菌的活性

2022-07-2936
PRE
Pseudomonas aeruginosa Community-Onset Bloodstream Infections: Characterization, Diagnostic Predictors, and Predictive Score Development-Results from the PRO-BAC Cohort
2022-05-244
OA